Pancreatic Cancer Research

ResearcherNorthwestern UniversityActive in the last 2 years

Huanwen Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3996-3176; OpenAlex author ID A5077592719. Sources: OpenAlex.

Their work

Papers
34 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
92
Papers, trials and grants by year

2015: 4 papers · 2016: 2 papers · 2017: 3 papers · 2018: 3 papers · 2019: 3 papers · 2020: 4 papers · 2021: 4 papers · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: 3 papers · 2026: 4 papers

Papers 34

  1. Tumor-Derived LAMB3 Drives Immunosuppressive LRRC15+ Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development. Co-author DOI 10.1002/advs.202520029↗
  2. Integrating Radiomics and Computational Pathology to Predict Early Recurrence of Pancreatic Ductal Adenocarcinoma and Uncover Its Biological Basis in Tumor Mic… Co-author DOI 10.1002/advs.202523985↗
  3. Tumor-educated adipocytes promote muscle wasting via EV-packaged miR-221-3p targeting IRS1 in pancreatic cancer cachexia. Co-author DOI 10.1016/j.canlet.2026.218795↗
  4. ALKBH5 in Cancer-Associated Fibroblasts Governs an Epitranscriptomic Axis That Drives Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-25-2950↗
  5. Labor-Efficient Pathological Auxiliary Diagnostic Model for Primary and Metastatic Tumor Tissue Detection in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.modpat.2025.100764↗
  6. S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure. Co-author DOI 10.1177/17588359251378698↗
  7. WFDC3 identified as a prognostic and immune biomarker in pancreatic cancer. Co-author DOI 10.17305/bb.2025.12444↗
  8. Pancreatic stellate cells exploit Wnt/β-catenin/TCF7-mediated glutamine metabolism to promote pancreatic cancer cells growth. Co-author DOI 10.1016/j.canlet.2022.216040↗
  9. A novel cuproptosis-related gene model predicts outcomes and treatment responses in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12885-023-10678-9↗
  10. Multi-omics analysis of intra-tumoural and inter-tumoural heterogeneity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ctm2.670↗
  11. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA. Co-author DOI 10.1186/s12916-022-02647-z↗
  12. Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes. Co-author DOI 10.1002/cam4.3679↗
  13. Dopamine improves chemotherapeutic efficacy for pancreatic cancer by regulating macrophage-derived inflammations. Co-author DOI 10.1007/s00262-020-02816-0↗
  14. A new prognosis prediction model combining TNM stage with MAP2K4 and JNK in postoperative pancreatic cancer patients. Co-author DOI 10.1016/j.prp.2020.153313↗
  15. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy. Co-author DOI 10.3389/fimmu.2021.690056↗
  16. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. First author DOI 10.1007/s00262-020-02542-7↗
  17. Pancreatic cancer with ovarian metastases: A case report and review of the literature. Co-author DOI 10.12998/wjcc.v8.i21.5380↗
  18. Upregulation of exosomal microRNA‑21 in pancreatic stellate cells promotes pancreatic cancer cell migration and enhances Ras/ERK pathway activity. First author DOI 10.3892/ijo.2020.4986↗
  19. AREG mediates the epithelial‑mesenchymal transition in pancreatic cancer cells via the EGFR/ERK/NF‑κB signalling pathway. Co-author DOI 10.3892/or.2020.7523↗
  20. High-molecular-weight hyaluronan produced by activated pancreatic stellate cells promotes pancreatic cancer cell migration via paracrine signaling. Co-author DOI 10.1016/j.bbrc.2019.05.167↗
  21. YAP1-mediated pancreatic stellate cell activation inhibits pancreatic cancer cell proliferation. Co-author DOI 10.1016/j.canlet.2019.07.015↗
  22. PSME3 Promotes TGFB1 Secretion by Pancreatic Cancer Cells to Induce Pancreatic Stellate Cell Proliferation. Co-author DOI 10.7150/jca.30235↗
  23. ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism. Co-author DOI 10.1158/1078-0432.ccr-18-0263↗
  24. PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay. Co-author DOI 10.1186/s13000-017-0678-4↗
  25. Retraction: PDZ-containing 1 acts as a suppressor of pancreatic cancer by regulating PTEN phosphorylation. Co-author DOI 10.18632/oncotarget.25033↗
  26. Asporin promotes pancreatic cancer cell invasion and migration by regulating the epithelial-to-mesenchymal transition (EMT) through both autocrine and paracrin… First author DOI 10.1016/j.canlet.2017.04.001↗
  27. Expression of signaling adaptor proteins predicts poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13000-017-0633-4↗
  28. PDZ-containing 1 acts as a suppressor of pancreatic cancer by regulating PTEN phosphorylation. Co-author DOI 10.18632/oncotarget.20552↗
  29. CT Imaging Biomarkers Predict Clinical Outcomes After Pancreatic Cancer Surgery. Co-author DOI 10.1097/md.0000000000002664↗
  30. Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma. First author DOI 10.1186/s13000-016-0512-4↗
  31. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13277-015-3690-x↗
  32. Catechol-O-methyltransferase, a new target for pancreatic cancer therapy. Co-author DOI 10.1111/cas.12648↗
  33. Coexpression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0116803↗
  34. Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells. First author DOI 10.18632/oncotarget.3099↗

Closest collaborators

The 25 strongest of 92 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhiyong Liang · 25 shared papers, 2015–2026 · strength 3.27
  2. Xiaoding Liu · 8 shared papers, 2021–2026 · strength 1.39
  3. Junliang Lu · 10 shared papers, 2016–2026 · strength 1.17
  4. Menghua Dai · 6 shared papers, 2020–2026 · strength 0.87
  5. Xuqing Shi · 3 shared papers, 2025–2026 · strength 0.76
  6. Ruiyu Li · 4 shared papers, 2021–2023 · strength 0.71
  7. Tonghua Liu · 8 shared papers, 2015–2020 · strength 0.67
  8. Bohan Liu · 2 shared papers, 2025–2026 · strength 0.54
  9. Zhiwen Zhang · 4 shared papers, 2018–2021 · strength 0.52
  10. Hangqi Liu · 3 shared papers, 2021–2026 · strength 0.52
  11. Xianlin Han · 2 shared papers, 2026 · strength 0.50
  12. Qixian Liu · 2 shared papers, 2023–2026 · strength 0.48
  13. Lianyuan Yu · 4 shared papers, 2019–2022 · strength 0.47
  14. Hui Zhang · 5 shared papers, 2015–2021 · strength 0.45
  15. Wenming Wu · 3 shared papers, 2015–2026 · strength 0.40
  16. Qiang Ma · 4 shared papers, 2017–2020 · strength 0.39
  17. Ying Xiao · 4 shared papers, 2017–2020 · strength 0.39
  18. Wei‐Min Tong · 2 shared papers, 2023–2026 · strength 0.38
  19. Huadan Xue · 3 shared papers, 2015–2026 · strength 0.35
  20. Xiaolong Liang · 3 shared papers, 2018–2021 · strength 0.33
  21. Boju Pan · 2 shared papers, 2020–2025 · strength 0.29
  22. Li Wang · 4 shared papers, 2015–2017 · strength 0.27
  23. Wanli Liu · 1 shared paper, 2026 · strength 0.26
  24. Aoyi Xiao · 1 shared paper, 2026 · strength 0.26
  25. Hui Jun Tang · 1 shared paper, 2025 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.